Akari TherapeuticsAKTX
13F holders, Q1 2026 (March 31)1holders −20
1new positions
20sold out
$0.12avg. 13F price*
At the end of Q1 2026, 1 institutions reported holding Akari Therapeutics PLC (AKTX) in their 13F filings, down 20 from Q4 2025. 1 opened new positions and 20 sold out. The largest holder was IFP Advisors, Inc ($877).
- Company
- Akari Therapeutics PLC
- CUSIP
- 00972G207
- Latest filing quarter
- Q1 2026
History
Number of 13F holders
Total Exit/New Position Q4 2025 → Q1 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $877 |
| Exits | 20 | $1.3M |
All 13F filers, Q4 2025 → Q1 2026: 7,250 shares bought and 4,432,281 shares sold, net −4,425,031 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 1 holders
| IFP Advisors, Inc | 0.00% | New | 7,250 | $877 |
"% of holder's portfolio" is AKTX's weight in each manager's 13F, not the share of Akari Therapeutics PLC the manager owns.